mRNA Cancer Vaccines Cut Recurrence Risk by 50%

Personalized cancer vaccines using mRNA technology are showing remarkable success in clinical trials, cutting melanoma recurrence rates in half.

The same breakthrough that brought us COVID-19 vaccines is now training immune systems to hunt down and destroy cancer cells.